Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models.
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Inhibition of tumor angiogenesis by blockading the vascular endothelial growth factor (VEGF) signaling pathway is a promising therapeutic strategy for thyroid cancer. Lenvatinib mesilate (lenvatinib) is a potent inhibitor of VEGF receptors (VEGFR1-3) and other prooncogenic and prooncogenic receptor tyrosine kinases, including fibroblast growth factor receptors (FGFR1-4), platelet derived growth factor receptor α (PDGFRα), KIT, and RET. We examined the antitumor activity of lenvatinib against human thyroid cancer xenograft models in nude mice. Orally administered lenvatinib showed significant antitumor activity in 5 differentiated thyroid cancer (DTC), 5 anaplastic thyroid cancer (ATC), and 1 medullary thyroid cancer (MTC) xenograft models. Lenvatinib also showed antiangiogenesis activity against 5 DTC and 5 ATC xenografts, while lenvatinib showed in vitro antiproliferative activity against only 2 of 11 thyroid cancer cell lines: that is, RO82-W-1 and TT cells. Western blot analysis showed that cultured RO82-W-1 cells overexpressed FGFR1 and that lenvatinib inhibited the phosphorylation of FGFR1 and its downstream effector FRS2. Lenvatinib also inhibited the phosphorylation of RET with the activated mutation C634W in TT cells. These data demonstrate that lenvatinib provides antitumor activity mainly via angiogenesis inhibition but also inhibits FGFR and RET signaling pathway in preclinical human thyroid cancer models.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Lenvatinib is an oral TKI of VEGFRs, FGFRs, PDGFRα, KIT, and RET.”
From Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma (2024) · cites this paper as [22]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Folkman, J., & Klagsbrun, M. (1987) · Science · doi:10.1126/science.2432664 · Cited by 3,491
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A
Mulligan, L. M., Kwok, J. B. J., Healey, C. S., Elsdon, M. J., Eng, C., Gardner, E., Love, D. R., Mole, S. E., Moore, J. K., Papi, L., et al. (1993) · Nature · doi:10.1038/363458a0 · Cited by 1,966
Induction of angiogenesis during the transition from hyperplasia to neoplasia
Folkman, J., Watson, K., Ingber, D., & Hanahan, D. (1989) · Nature · doi:10.1038/339058a0 · Cited by 1,879
Brose, M. S., Nutting, C. M., Jarzab, B., Elisei, R., Siena, S., Bastholt, L., de la Fouchardiere, C., Pacini, F., Paschke, R., Shong, Y. K., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60421-9 · Cited by 1,663
Wells, S. A., Robinson, B. G., Gagel, R. F., Dralle, H., Fagin, J. A., Santoro, M., Baudin, E., Elisei, R., Jarzab, B., Vasselli, J. R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.5040 · Cited by 1,559
Molecular pathogenesis and mechanisms of thyroid cancer
Xing, M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3431 · Cited by 1,426
Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC
Donis-Keller, H., Dou, S., Chi, D., Carlson, K. M., Toshima, K., Lairmore, T. C., Howe, J. R., Moley, J. F., Goodfellow, P., & Wells, S. A. (1993) · Human Molecular Genetics · doi:10.1093/hmg/2.7.851 · Cited by 1,303
Research works printed but not linked: 1
- 2002, Cancer Research, 62, 5749
Cited by
Items 301–400 of 505
Zhao, M., Li, R., Song, Z., Miao, C., & Lu, J. (2024) · Medicine · doi:10.1097/md.0000000000037655 · Cited by 7
Effects of three flavonoids on the metabolism of lenvatinib
Yang, J., Chen, J., Li, Q.-Q., Xu, R.-A., & Chen, X. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1438259 · Cited by 7
Wang, X., Qian, S., Wang, S., Jia, S., Zheng, N., Yao, Q., & Gao, J. (2023) · PeerJ · doi:10.7717/peerj.14610 · Cited by 7
Aoyama, M., Takizawa, H., Otani, T., Inoue, S., Kawakita, N., Tsuboi, M., Bando, Y., Uehara, H., Kondo, K., & Tangoku, A. (2020) · Oncology Reports · doi:10.3892/or.2020.7720 · Cited by 7
A real-world drug safety surveillance study of lenvatinib from the FAERS database
Yang, Y., Wang, Y., Chen, B., Liu, Y., & Gu, K. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2393284 · Cited by 7
Severe skin ulcer caused by taking lenvatinib after proton beam therapy
Iwasa, T., Adachi, S., Ogiso, H., Takada, E., Mabuchi, M., Suzuki, Y., Yamauchi, O., Saito, K., Iwashita, T., Ogino, H., et al. (2023) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-023-01802-0 · Cited by 7
Iwaki, S., Kawakita, D., Sawabe, M., Matoba, T., Takano, G., Oguri, K., Murashima, A., Minohara, K., Tanaka, N., Tsuge, H., et al. (2021) · Auris Nasus Larynx · doi:10.1016/j.anl.2021.06.005 · Cited by 7
Tyrosine Kinase Inhibitors for the Therapy of Anaplastic Thyroid Cancer
Antonelli, A., Fallahi, P., Ulisse, S., Ferrari, S. M., Mazzi, V., Domenicantonio, A. D., & Miccoli, P. (2015) · International Journal of Endocrine Oncology · doi:10.2217/ije.15.4 · Cited by 7
Ascari, S., Chen, R., Sinno, A. D., Stefanini, B., Cescon, M., Serenari, M., Mosconi, C., & Tovoli, F. (2026) · World Journal of Gastroenterology · doi:10.3748/wjg.v32.i3.111528 · Cited by 6
A Phase 1b Study of Lenvatinib plus Nivolumab in Patients with Unresectable Hepatocellular Carcinoma
Ikeda, M., Kudo, M., Motomura, K., Okusaka, T., Kato, N., Hisai, T., Ikezawa, H., Shiba, S., Hoshi, T., Kuroda, M., et al. (2026) · Liver Cancer · doi:10.1159/000549681 · Cited by 6
Liverani, C., Spadazzi, C., Ibrahim, T., Pieri, F., Foca, F., Calabrese, C., Vita, A. D., Miserocchi, G., Cocchi, C., Vanni, S., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1045038 · Cited by 6
Rousset, P., Nardin, C., Maubec, E., Heidelberger, V., Picard, A., Troin, L., Gerard, É., Kramkimel, N., Steff, M., Quereux, G., et al. (2024) · The Oncologist · doi:10.1093/oncolo/oyae145 · Cited by 6
Ueshima, E., Sofue, K., Takaki, H., Hirata, Y., Kodama, H., Okada, T., Yamaguchi, M., Yamakado, K., & Murakami, T. (2023) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2023.07.025 · Cited by 6
Kuwano, A., Tanaka, K., Yada, M., Nagasawa, S., Morita, Y., Masumoto, A., & Motomura, K. (2021) · Molecular and Clinical Oncology · doi:10.3892/mco.2021.2486 · Cited by 6
Uekusa, S., Nemoto, M., Hanai, Y., Nakashin, M., Miyagawa, A., Yanagino, S., Arita, Y., Μatsumoto, T., Nishizawa, K., Nagai, H., et al. (2023) · Pharmacology · doi:10.1159/000531881 · Cited by 6
Chen, R., Li, L., Li, Y., Song, K., Shen, C., Ma, P., & Wang, Z. K. (2022) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-22-525 · Cited by 6
Shibata, O., Kamimura, K., Ko, M., Sakai, N., Abé, H., Morita, S., Mizusawa, T., Sato, H., Sakamaki, A., & Terai, S. (2020) · Internal Medicine · doi:10.2169/internalmedicine.6580-20 · Cited by 6
Borriello, R., Cerrito, L., Gasbarrini, A., & Ponziani, F. R. (2023) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2023.2272598 · Cited by 6
Xie, Q., Chen, H., Ai, J., Gao, Y., Geng, M., Ding, J., & Chen, Y. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.107 · Cited by 6
Lenvatinib: an investigational agent for the treatment of differentiated thyroid cancer
Ferrari, S. M., Elia, G., Ragusa, F., Paparo, S. R., Mazzi, V., Miccoli, M., Galdiero, M. R., Varricchi, G., Foddis, R., Guglielmi, G., et al. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1972971 · Cited by 6
Kosaka, Y., Kawaoka, T., Aikata, H., Suehiro, Y., Yamaoka, K., Ando, Y., Namba, M., Takeuchi, Y., Fujii, Y., Uchikawa, S., et al. (2020) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-020-01093-9 · Cited by 6
Self-citationColitis induced by Lenvatinib in a patient with advanced hepatocellular carcinoma
Miyajima, S., Tsuji, K., Kito, Y., Yoshida, N., Matsunaga, K., Tsuji, S., Katayanagi, K., Yonezawa, M., Kubo, A., Ushijima, K., et al. (2020) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-020-01249-7 · Cited by 6
Brose, M. S., Worden, F. P., Newbold, K. L., Guo, M., & Hurria, A. (2018) · Head and neck tumors (HNT) · doi:10.17650/2222-1468-2018-8-2-39-52 · Cited by 6
Bai, Y., Hu, X., Ren, Z., Hisai, T., Yusa, W., Weng, L., Shiba, S., & Takase, T. (2022) · Future Oncology · doi:10.2217/fon-2022-0229 · Cited by 6
Targeted Molecular Therapeutic Options for Hepatocellular Carcinoma
Sridhar, S., Sharma, I., Sankpal, U. T., Ghabach, B., Narra, K., Neerukonda, L. S., & Basha, R. M. (2020) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2020034985 · Cited by 6
Nakahara, M., Fujihara, S., Iwama, H., Takuma, K., Oura, K., Tadokoro, T., Fujita, K., Tani, J., Morishita, A., Kobara, H., et al. (2022) · Biomedical Reports · doi:10.3892/br.2022.1561 · Cited by 6
Anaplastic Thyroid Carcinoma Treated with Lenvatinib
Ohkubo, J., Takahashi, A., Ikezaki, S., Takenaga, F., Ohkubo, Y., & Suzuki, H. (2017) · The Kurume Medical Journal · doi:10.2739/kurumemedj.ms6406 · Cited by 6
Watanabe, T., & Koyama, N. (2019) · Folia Pharmacologica Japonica · doi:10.1254/fpj.153.242 · Cited by 6
Uchikawa, S., Kawaoka, T., Fujino, H., Ono, A., Nakahara, T., Murakami, E., Yamauchi, M., Miki, D., Imamura, M., & Aikata, H. (2022) · Journal of Medical Ultrasonics · doi:10.1007/s10396-022-01260-0 · Cited by 6
Zaki, I. H., & Imam, A. M. (2020) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162020060096 · Cited by 6
Hatanaka, T., Kakizaki, S., Nagashima, T., Ueno, T., Namikawa, M., Tojima, H., Takizawa, D., Naganuma, A., Arai, H., Sato, K., et al. (2021) · Acta gastro-enterologica belgica · doi:10.51821/84.1.109 · Cited by 5
Advances in lenvatinib monotherapy and combination therapies in anaplastic thyroid cancer (Review)
Xu, L., Zhang, W., Wang, Y., Le, Q., Xie, Y., Yu, K., & Wu, X. (2025) · Oncology Letters · doi:10.3892/ol.2025.15139 · Cited by 5
miR-3191 promotes the proliferation and metastasis of hepatocellular carcinoma via regulating PAK6
Xie, A., Wang, H., Huang, J., Sun, M., & Chen, L. (2024) · Infectious Agents and Cancer · doi:10.1186/s13027-024-00628-w · Cited by 5
Tsuruoka, M., Ninomiya, M., Inoue, J., Iwata, T., Sano, A., Sato, K., Onuki, M., Sawahashi, S., & Masamune, A. (2024) · Oncology · doi:10.1159/000540438 · Cited by 5
Evolving therapeutic strategies for advanced hepatocellular carcinoma
Qureshi, A., Michel, M., Lerner, J., & Dasanu, C. A. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1953473 · Cited by 5
Lin, Z., Yeh, M., Liang, P., Hsu, P., Huang, C., Huang, J., Dai, C., Yu, M., & Chuang, W. (2023) · Cancers · doi:10.3390/cancers15205097 · Cited by 5
Lenvatinib-refractory thymic mucinous carcinoma with PIK3CA mutation
Tsukaguchi, A., Ihara, S., Yasuoka, H., & Minami, S. (2022) · International Cancer Conference Journal · doi:10.1007/s13691-022-00573-8 · Cited by 5
A Multidisciplinary Treatment Strategy With Conversion Surgery for Hepatocellular Carcinoma
Shiozaki, H., Furukawa, K., Haruki, K., Matsumoto, M., Uwagawa, T., Onda, S., Yamahata, Y., Ishizaki, S., Abe, K., FUJIOKA, S., et al. (2023) · Anticancer Research · doi:10.21873/anticanres.16329 · Cited by 5
A feasibility study of lenvatinib plus pembrolizumab in Japanese patients with advanced solid tumors
Kitano, S., Fujiwara, Y., Shimizu, T., Iwasa, S., Yonemori, K., Kondo, S., Shimomura, A., Koyama, T., Ebata, T., Ikezawa, H., et al. (2022) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-022-04480-w · Cited by 5
Self-citationKimura, M., Go, M., Yamada, S., Asano, H., Usami, E., & Yoshimura, T. (2023) · Oncology Letters · doi:10.3892/ol.2023.13736 · Cited by 5
Alqahtani, S. A., & Colombo, M. G. (2021) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v13.i12.2038 · Cited by 5
Yagishita, H., Minami, S., Akamine, Y., Kato, S., Iijima, K., & Miura, M. (2019) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13030 · Cited by 5
Endo, M., Honda, K., Saito, T., Shiraiwa, K., Sueshige, Y., Tokumaru, T., Iwao, M., Tokoro, M., Arakawa, M., Tanaka, R., et al. (2021) · World Journal of Oncology · doi:10.14740/wjon1399 · Cited by 5
Wang, M., Yao, X., Bo, Z., Zheng, J., Yu, H., Xie, X., Lin, Z., Wang, Y., Chen, G., & Wu, L. (2023) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s395474 · Cited by 4
Transplant oncology and immunotherapy: Immunotherapy and liver transplants
Abdelrahim, M., & Esmail, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21901-6.00008-2 · Cited by 4
Yoshikawa, T., Endo, K., Moriyama‐Kita, M., Ueno, T., Nakanishi, Y., Dochi, H., Uno, D., Kondo, S., & Yoshizaki, T. (2024) · Auris Nasus Larynx · doi:10.1016/j.anl.2024.04.008 · Cited by 4
Development of a Microvessel Density Gene Signature and Its Application in Precision Medicine
Kuronishi, M., Ozawa, Y., Kimura, T., Li, S. D., & Kato, Y. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0403 · Cited by 4
Self-citationRohilla, J., Mishra, R., Varshney, S., Mazumder, A., Mazumder, R., Kumar, A., & Kaur, A. (2024) · Current Organic Chemistry · doi:10.2174/0113852728307286240517054021 · Cited by 4
Zhao, L., Zhang, Z., Wang, D., Liu, Y., Liu, Z., & Lou, C. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01623-0 · Cited by 4
Uchida‐Kobayashi, S., Kageyama, K., Takemura, S., Matsumoto, K., Odagiri, N., Jogo, A., Kotani, K., Kozuka, R., Motoyama, H., Kawamura, E., et al. (2022) · JGH Open · doi:10.1002/jgh3.12819 · Cited by 4
Peck‐Radosavljevic, M., Abdelgafur, A., Granito, A., Gasbarrini, A., Ma, Y. T., Mena, E., Lledó-Navarro, J. L., Presa, J., Weinmann, A., Levy, M. T., et al. (2026) · Liver Cancer · doi:10.1159/000552115 · Cited by 4
Lin, C., Chien, R., Chen, L., Chu, Y., & Yeh, C. (2023) · Cancer Biomarkers · doi:10.3233/cbm-220042 · Cited by 4
Tsuruoka, A., Matsui, J., Suzuki, T., Koyama, N., Watanabe, T., & Funahashi, Y. (2015) · Folia Pharmacologica Japonica · doi:10.1254/fpj.146.283 · Cited by 4
Self-citationShumaker, R. C., Ren, M., Aluri, J., Dutcus, C. E., Rance, C., & He, C. S. (2020) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-020-00607-7 · Cited by 4
Kishikawa, M., Inoue, J., Hamamoto, H., Kobayashi, K., Asakage, T., & Inazawa, J. (2021) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2021.101009 · Cited by 4
Furuse, J., Izumi, N., Motomura, K., Inaba, Y., Katamura, Y., Kondo, Y., Yabushita, K., Matsuoka, T., Motoyoshi, K., & Kudo, M. (2025) · Cancers · doi:10.3390/cancers17030479 · Cited by 4
Kimura, M., Yamada, S., Go, M., Yasuda, S., Toyoda, H., & Usami, E. (2024) · Oncology Letters · doi:10.3892/ol.2024.14464 · Cited by 4
Tian, Y., Jin, W., Sun, H., Jin, D., Kang, D., Li, Z., & Piao, L. (2023) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s426174 · Cited by 4
Recent advances in precision medicine for the treatment of anaplastic thyroid cancer
Ferrari, S. M., Fallahi, P., Motta, C. L., Elia, G., Ragusa, F., Ruffilli, I., Patrizio, A., Baldini, E., Ulisse, S., & Antonelli, A. (2019) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2019.1565940 · Cited by 4
Wang, X., Mou, Y., Yue, Z., Zhang, H., Su, X., Wang, Y., Li, R., & Sun, X. (2016) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2016.07.009 · Cited by 4
Sugimoto, R., Inada, H., Tanaka, Y., Senju, T., Aratake, Y., Nakanishi, A., Miki, M., Lee, L., Hisano, T., Matsumoto, Y., et al. (2021) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-021-01470-y · Cited by 4
Osaki, R., Iida, H., Noda, S., Fujimoto, T., Wakasugi, Y., Terada, T., Tani, M., & Andoh, A. (2021) · Kanzo · doi:10.2957/kanzo.62.80 · Cited by 3
Wang, C., Feng, W. Q., Sun, X., Qiu, W., Yu, Y., Sun, D., Yao, Z., Li, J., Fan, Z., Lv, G., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1429919 · Cited by 3
Polypharmacology in Clinical Applications—Anticancer Polypharmacology
Wang, Z., & Yang, B. (2022) · Springer eBooks · doi:10.1007/978-3-031-04998-9_3 · Cited by 3
Reviewing the Synthesis and Clinical Application of FDA-approved Anticancer Medications
Johariya, V., Sharma, S., Mali, S. N., & Banik, B. K. (2024) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266321816240822060818 · Cited by 3
Zheng, L., Tao, C., Tao, Z., Zhang, K., Wu, A., Wu, J., & Rong, W. (2021) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v13.i10.1136 · Cited by 3
Shao, X., Wáng, Y., Lu, X., Hu, Y., Liao, J., Li, J., Chen, X., Yu, Y., Ai, N., Ying, M., et al. (2020) · iScience · doi:10.1016/j.isci.2020.101748 · Cited by 3
Autophagy in thyroid cancer: Immune suppression and drug resistance
Zhai, H., Sun, P., Bashir, B., Qu, B., Du, Z., Kumar, A. P., Xia, Y., Gangadaran, P., Jha, S. K., Singh, S. K., et al. (2026) · Drug Resistance Updates · doi:10.1016/j.drup.2026.101437 · Cited by 3
Recent progress of small-molecule of RET inhibitors against Non-small cell lung cancer
Shen, J., Chen, L., Song, Y., Chen, S., Guo, W., & Li, Y.-D. (2024) · AAPS Open · doi:10.1186/s41120-024-00094-z · Cited by 3
Kao, Y.-C. (2024) · American Journal of Cancer Research · doi:10.62347/ykzb8359 · Cited by 3
Jin, M., Kim, C. A., Bae, D. J., Kim, S., Kim, T. Y., Kim, W. B., Shong, Y. K., Kim, W. G., & Jeon, M. J. (2023) · Scientific Reports · doi:10.1038/s41598-023-39503-w · Cited by 3
GianAA, F., Tumino, D., & Frasca, F. (2016) · Endocrinology & Metabolic Syndrome · doi:10.4172/2161-1017.1000251 · Cited by 3
Brose, M. S., Panaseykin, Y., Konda, B., de la Fouchardière, C., Hughes, B. G. M., Gianoukakis, A. G., Park, Y. J., Romanov, I., Krzyzanowska, M. K., Leboulleux, S., et al. (2022) · Head and neck tumors (HNT) · doi:10.17650/2222-1468-2022-12-1-86-98 · Cited by 3
Aoki, Y., Inoue, Y., Sasahira, N., Ono, M., Inamura, K., Kataoka, A., Takano, T., Kanao, H., & Watanabe, M. (2023) · Oncology Letters · doi:10.3892/ol.2023.14037 · Cited by 3
Ten years-experience of sunitinib in the treatment of advanced pan-NETs: an update on safety profile
Vivanet, G., Gervaso, L., Laffi, A., Rubino, M., Spada, F., & Fazio, N. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2000964 · Cited by 3
Rodia, R., Marini, S., Pani, F., Boi, F., & Mariotti, S. (2019) · Future Oncology · doi:10.2217/fon-2019-0184 · Cited by 3
Wang, X., Li, Y., Mou, Y., Yue, Z., Zhang, H., Li, R., & Sun, H. (2018) · International Journal of Medical Sciences · doi:10.7150/ijms.28337 · Cited by 3
Case Study on Receptor Tyrosine Kinases EGFR, VEGFR, and PDGFR
Lima, L. M., Barbosa, M. L. D. C., do Amaral, D. N., & Barreiro, E. J. (2020) · Topics in medicinal chemistry · doi:10.1007/7355_2020_95 · Cited by 2
The potential of lenvatinib in breast cancer therapy
Shang, Y., Liu, Y., & Wang, W. (2024) · Medical Oncology · doi:10.1007/s12032-024-02477-4 · Cited by 2
Zhang, C., Sun, M., Shi, Y., Cui, J., Mao, Y., Lin, Z., Wu, X., Li, S., & Nan, Y. (2025) · Cancer Cell International · doi:10.1186/s12935-025-04147-5 · Cited by 2
Cruz, F. S. D., Fox, E., DuBois, S. G., Friedman, G. K., Croop, J. M., Kim, A., Morgenstern, D. A., Balis, F. M., Macy, M. E., Pressey, J. G., et al. (2025) · Pediatric Blood & Cancer · doi:10.1002/pbc.31692 · Cited by 2
Development of Lenvatinib Mesylate, an Angiogenesis Inhibitor Targeting VEGF and FGF Receptors
Tsuruoka, A., Funahashi, Y., Matsui, J., & Matsushima, T. (2019) · Wiley eBooks · doi:10.1002/9783527814695.ch6 · Cited by 2
Self-citationYang, T., Wei, T., Sun, S., Xi, B., Wei, P., Jia, C., Qi, Z., Feng, F., Wei, M., Wang, Y., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03743 · Cited by 2
Fujita, K., Suzuki, A., Nagahama, M., Sugino, K., Masaki, C., Ito, K., & Miura, M. (2024) · Drugs - Real World Outcomes · doi:10.1007/s40801-024-00467-6 · Cited by 2
Cabanillas, M. E., & Takahashi, S. (2019) · Head and neck tumors (HNT) · doi:10.17650/2222-1468-2019-9-4-49-61 · Cited by 2
Mahipal, A., Cheng, A., Kudo, M., Burgoyne, A. M., Kalyan, A., Lencioni, R. A., López, C., Daniele, B., Palmer, D. H., Baron, A. D., et al. (2026) · Liver Cancer · doi:10.1159/000551313 · Cited by 2
Lu, H., Liang, B., Zheng, C., & Xia, X. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-04419-4 · Cited by 2
Komeda, Y., Nagamatsu, S., Kaya, D., Sueki, A., Yamamoto, C., Ohta, K., Matsuo, Y., Nishio, Y., Kikukawa, S., Matsuura, K., et al. (2024) · Internal Medicine · doi:10.2169/internalmedicine.3907-24 · Cited by 2
A report of a new late toxic effect of lenvatinib
Yuan, B., Zhang, J., Wang, M., Wang, Y., Yan, J., Wang, X., & Fu, J. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000000690 · Cited by 2
Kimura, M., Asano, H., Usami, E., Teramachi, H., & Yoshimura, T. (2022) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552221145475 · Cited by 2
Kimura, M., Yamada, S., Go, M., Yasuda, S., Toyoda, H., & Usami, E. (2024) · Cancer Diagnosis & Prognosis · doi:10.21873/cdp.10297 · Cited by 2
Systematic review of the efficacy and safety of lenvatinib in various solid tumors
Geng, S., Liu, T., Wang, N., Gao, X., Luo, X., Shi, N., & Jiang, S. (2024) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2024.2344153 · Cited by 2
Pneumothorax during lenvatinib plus pembrolizumab for recurrent endometrial cancer: A case report
Taguchi, M., Takahashi, Y., Nakamura, M., Takei, Y., & Fujiwara, H. (2025) · Taiwanese Journal of Obstetrics and Gynecology · doi:10.1016/j.tjog.2025.03.016 · Cited by 2
Oura, K., Takuma, K., Nakahara, M., Tadokoro, T., Fujita, K., Mimura, S., Tani, J., Morishita, A., Kobara, H., & Masaki, T. (2021) · Molecular and Clinical Oncology · doi:10.3892/mco.2021.2316 · Cited by 2
Immunotherapy in Chemorefractory Endometrial Cancer: Ray of Hope?
Mahajan, D., Kalnawat, N., Paliwal, V., & Tongaonkar, H. B. (2023) · Indian Journal of Gynecologic Oncology · doi:10.1007/s40944-023-00733-5 · Cited by 2
Masaki, C., Shioya, J., Sugino, K., Terasawa, Y., Yokotsuka, S., Nakata, M., Kitagawa, W., & Ito, K. (2023) · Supportive Care in Cancer · doi:10.1007/s00520-023-08163-x · Cited by 1
Masoudi-Khoram, N., Cheraghi, S., Nazari, M., & Khamseh, M. E. (2025) · Medical Oncology · doi:10.1007/s12032-025-02788-0 · Cited by 1
Zhu, Y., Huang, Y., Song, M., Yang, J., Zhao, J., Tang, Y., Ouyang, D., Yang, C., Chen, Y., Wang, Q., et al. (2026) · Cell Death and Disease · doi:10.1038/s41419-026-08735-9 · Cited by 1
Multidisciplinary fatigue management in patients treated with lenvatinib
Zenda, S., Ikeda, M., Kawaguchi, T., Shomura, M., Miyazawa, Y., Tauchi, J., Koya, S., & Endô, K. (2021) · Kanzo · doi:10.2957/kanzo.62.601 · Cited by 1
Rurua, N., Gogiashvili, L., & Tsagareli, Z. (2015) · Basic & Clinical Medicine · Cited by 1
Metadata
- Authors
- Tohyama, O., Matsui, J., Kodama, K., Hata-Sugi, N., Kimura, T., Okamoto, K., Minoshima, Y., Iwata, M., & Funahashi, Y.
- Affiliations
- Eisai (Japan) (JP)
- Eisai (United States) (US)
- Corresponding author
- Funahashi, Yasuhiro
- ORCID
- Venue
- Journal of Thyroid Research
- Publisher
- Wiley
- Published
- 2014
- Volume
- 2014
- Pages
- 1-13
- ISSN
- 2042-0072 (ISSN-L)
- 2090-8067
- PMC
- PMC4177084
- OpenAlex
- W2094109552
- Cited by
- 475
- References
- 50
- Citations by year
- 2026: 18 · 2025: 22 · 2024: 49 · 2023: 69 · 2022: 57 · 2021: 69 · 2020: 52 · 2019: 53 · 2018: 38 · 2017: 17 · 2016: 18 · 2015: 12 · 2014: 1
- FWCI
- 13.15
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Journal of Thyroid Research (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Keywords
- lenvatinib, thyroid cancer, angiogenesis inhibition, VEGF receptor signaling, FGFR1, RET, receptor tyrosine kinase inhibitors, anaplastic thyroid carcinoma, medullary thyroid carcinoma, differentiated thyroid cancer, xenograft models, antiproliferative activity, FRS2, KIT, PDGFRA
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.